The Medical Letter on Drugs and Therapeutics
Brinzolamide/Brimonidine (Simbrinza) for Glaucoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Simbrinza (Alcon), an ophthalmic combination of the carbonic anhydrase inhibitor brinzolamide and the selective alpha2-adrenergic receptor agonist brimonidine, for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Simbrinza is the first product to combine drugs from these 2 classes.

STANDARD TREATMENT — For initial treatment of glaucoma, a prostaglandin analog is preferred. Dosed once daily, prostaglandin analogs typically lower IOP by 25-30% and stabilize it at a lower level throughout the day and night. They have few, if any, systemic effects.

Topical beta blockers such as timolol are also commonly used; they lower IOP by 20-25% with once- or twice-daily dosing, but their use as first-line therapy has been limited by systemic adverse effects such as fatigue, dizziness, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Brinzolamide Brimonidine (Simbrinza) for Glaucoma
Article code: 1421a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian